Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Jun 25;12(6):e228806.
doi: 10.1136/bcr-2018-228806.

Neonatal diabetes mellitus: remission induced by novel therapy

Pradip Dalwadi  1 , Ameya S Joshi  1 , Darshana Sudip Thakur  1 , Nikhil M Bhagwat  1
Affiliations
Case Reports

Neonatal diabetes mellitus: remission induced by novel therapy

Pradip Dalwadi et al. BMJ Case Rep. .

Abstract

A female child with deafness was diagnosed to have neonatal diabetes mellitus at the age of 6 months, on routine evaluation prior to cochlear implant surgery. She presented to us at 11 months of age with diabetic ketoacidosis due to an intercurrent febrile illness. Her haematological parameters showed megaloblastic anaemia and thrombocytopenia. Therefore a possibility of Thiamine Responsive Megaloblastic Anaemia (TRMA) syndrome was considered. She was empirically treated with parenteral thiamine hydrochloride (Hcl). Subsequently, due to the unavailability of pharmacological preparation of oral thiamine Hcl in a recommended dose she was treated with benfotiamine. She had a sustained improvement in all her haematological parameters on oral benfotiamine. The insulin requirement progressively reduced and she is currently in remission for last 2 years. The genetic analysis confirmed the diagnosis of TRMA syndrome. Thus benfotiamine can be considered a new treatment option in management of TRMA syndrome.

Keywords: diabetes; endocrine system; haematology (incl blood transfusion); neonatal and paediatric intensive care; paediatrics (drugs and medicines).

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Bone marrow examination.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Porter FS, Rogers LE, Sidbury JB, et al. . Thiamine-responsive megaloblastic anemia. J Pediatr 1969;74:494–504. 10.1016/S0022-3476(69)80031-4 - DOI - PubMed
    1. Stagg AR, Fleming JC, Baker MA, et al. . Defective high-affinity thiamine transporter leads to cell death in thiamine-responsive megaloblastic anemia syndrome fibroblasts. J Clin Invest 1999;103:723–9. 10.1172/JCI3895 - DOI - PMC - PubMed
    1. Labay V, Raz T, Baron D, et al. . Mutations in SLC19A2 cause thiamine-responsive megaloblastic anaemia associated with diabetes mellitus and deafness. Nat Genet 1999;22:300–4. 10.1038/10372 - DOI - PubMed
    1. Dutta B, Huang W, Molero M, et al. . Cloning of the human thiamine transporter, a member of the folate transporter family. J Biol Chem 1999;274:31925–9. 10.1074/jbc.274.45.31925 - DOI - PubMed
    1. Meire FM, Van Genderen MM, Lemmens K, et al. . Thiamine-responsive megaloblastic anemia syndrome (TRMA) with cone-rod dystrophy. Ophthalmic Genet 2000;21:243–50. 10.1076/1381-6810(200012)2141-HFT243 - DOI - PubMed

Publication types

MeSH terms

Supplementary concepts